医学信息
醫學信息
의학신식
MEDICAL INFORMATION
2014年
26期
80-81
,共2页
伊班膦酸%复方苦参注射液%骨转移癌%骨痛
伊班膦痠%複方苦參註射液%骨轉移癌%骨痛
이반련산%복방고삼주사액%골전이암%골통
Ibandronate%Compound Kushen injection%Ostealgia%Osseous metastasis
目的观察伊班膦酸联合复方苦参注射液治疗恶性肿瘤骨转移癌骨痛的有效性和安全性。方法选取2012年6月~2013年12月于我院肿瘤科治疗的70例恶性肿瘤骨转移患者,其中38例为治疗组接受伊班膦酸联合复方苦参注射液治疗,32例为对照组给予伊班膦酸钠单药治疗。治疗组给予伊班膦酸4 mg加入0.9%氯化钠注射液500 mL,静脉滴注120 min,复方苦参注射液20 mL加入0.9%氯化钠注射液250 mL静脉滴注,d1~14,每4 w重复1次；对照组单用伊班膦酸,方法同治疗组。观察8 w内患者骨痛及体力改善情况。结果治疗组38例患者中有34例骨痛得到了不同程度的缓解,其中20例显效,14例有效,4例无效,有效率为89.5%；对照组32例患者中15例显效,11例有效,6例无效,有效率为81.2%；治疗组有效率高于对照组(<0.05),差异有统计学意义。结论伊班膦酸联合复方苦参注射液对恶性肿瘤骨转移癌引起的骨痛具有良好的治疗作用,毒副反应较轻微。
目的觀察伊班膦痠聯閤複方苦參註射液治療噁性腫瘤骨轉移癌骨痛的有效性和安全性。方法選取2012年6月~2013年12月于我院腫瘤科治療的70例噁性腫瘤骨轉移患者,其中38例為治療組接受伊班膦痠聯閤複方苦參註射液治療,32例為對照組給予伊班膦痠鈉單藥治療。治療組給予伊班膦痠4 mg加入0.9%氯化鈉註射液500 mL,靜脈滴註120 min,複方苦參註射液20 mL加入0.9%氯化鈉註射液250 mL靜脈滴註,d1~14,每4 w重複1次；對照組單用伊班膦痠,方法同治療組。觀察8 w內患者骨痛及體力改善情況。結果治療組38例患者中有34例骨痛得到瞭不同程度的緩解,其中20例顯效,14例有效,4例無效,有效率為89.5%；對照組32例患者中15例顯效,11例有效,6例無效,有效率為81.2%；治療組有效率高于對照組(<0.05),差異有統計學意義。結論伊班膦痠聯閤複方苦參註射液對噁性腫瘤骨轉移癌引起的骨痛具有良好的治療作用,毒副反應較輕微。
목적관찰이반련산연합복방고삼주사액치료악성종류골전이암골통적유효성화안전성。방법선취2012년6월~2013년12월우아원종류과치료적70례악성종류골전이환자,기중38례위치료조접수이반련산연합복방고삼주사액치료,32례위대조조급여이반련산납단약치료。치료조급여이반련산4 mg가입0.9%록화납주사액500 mL,정맥적주120 min,복방고삼주사액20 mL가입0.9%록화납주사액250 mL정맥적주,d1~14,매4 w중복1차；대조조단용이반련산,방법동치료조。관찰8 w내환자골통급체력개선정황。결과치료조38례환자중유34례골통득도료불동정도적완해,기중20례현효,14례유효,4례무효,유효솔위89.5%；대조조32례환자중15례현효,11례유효,6례무효,유효솔위81.2%；치료조유효솔고우대조조(<0.05),차이유통계학의의。결론이반련산연합복방고삼주사액대악성종류골전이암인기적골통구유량호적치료작용,독부반응교경미。
Objective To evaluate the curative ef icacy and safety of ibandronate Combined with Compound Kushen Injection for treating ostealgia in patients with malignant tumor and osseous metastases.Methods Between Jun.2012 and Dec-2013,70 patients with malignant tumor and osseous metastases were enrol ed in our study,of whom,38 were assigned to trial group treated with compound Kushen injection ( 20 mL) that was added to 250 mL 0.9%sodium chloride injection by ivgt for two weeks combined with ibandronate acid ( 4 mg) that was added to 100 mL 0.9%sodium chloride injection by ivgtt within 15 min ( this therapy was repeated in every 4 weeks) and 32 to receive ibandronate acid alone which was administered at the same dosage and administration as in the trial group (control group) .Ostealgia degree and physical strength improvement were observed within treatment of eight weeks.Results The overal response rate was 89.5% in the trial group ( 34 showed improvement,with 20 showing excellent response,14 response and 4 no response) vs.81.2% ( 15 showed excellent response,11 response and 6 no response) in the control group ( <0.05).Conclusion Ibandronate Combined with Compound Kushen Injection showed goof efficacy yet mild toxicity for ostealgia in cancer patients with osseous metastases.
